BRPI0512941A - antibióticos de peptìdeo e métodos para fazer os mesmos - Google Patents

antibióticos de peptìdeo e métodos para fazer os mesmos

Info

Publication number
BRPI0512941A
BRPI0512941A BRPI0512941-9A BRPI0512941A BRPI0512941A BR PI0512941 A BRPI0512941 A BR PI0512941A BR PI0512941 A BRPI0512941 A BR PI0512941A BR PI0512941 A BRPI0512941 A BR PI0512941A
Authority
BR
Brazil
Prior art keywords
peptides
methods
polymyxin
same
peptide antibiotics
Prior art date
Application number
BRPI0512941-9A
Other languages
English (en)
Inventor
Richard A Leese
Noreen Francis
William V Curran
Donald B Borders
Howard Jarolmen
Original Assignee
Biosource Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosource Pharm Inc filed Critical Biosource Pharm Inc
Publication of BRPI0512941A publication Critical patent/BRPI0512941A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

ANTIBIóTICOS DE PEPTìDEO E MéTODOS PARA FAZER OS MESMOS. A presente invenção refere-se a novos peptídeos e peptídeos protegidos. Estes compostos podem ser derivados de peptídeos de ocorrência natural, como aqueles selecionados de colistina, circulina A, polimixina A, polimixina B, polimixina D, octapeptina B, octapeptina C e ¢IIe¬ 7¬!polimixina B~ 1~. Também descritos são composições farmacêuticas contendo os novos peptídeos, como também métodos para preparar os novos peptídeos e peptídeos protegidos.
BRPI0512941-9A 2004-07-01 2005-07-01 antibióticos de peptìdeo e métodos para fazer os mesmos BRPI0512941A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/881,160 US20060004185A1 (en) 2004-07-01 2004-07-01 Peptide antibiotics and peptide intermediates for their prepartion
PCT/US2005/023343 WO2006083317A2 (en) 2004-07-01 2005-07-01 Peptide antibiotics and methods for making same

Publications (1)

Publication Number Publication Date
BRPI0512941A true BRPI0512941A (pt) 2007-10-30

Family

ID=35514884

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512941-9A BRPI0512941A (pt) 2004-07-01 2005-07-01 antibióticos de peptìdeo e métodos para fazer os mesmos

Country Status (15)

Country Link
US (2) US20060004185A1 (pt)
EP (2) EP2332965A1 (pt)
JP (2) JP2008505858A (pt)
KR (1) KR20070047770A (pt)
CN (1) CN101010336A (pt)
AU (1) AU2005326770B2 (pt)
BR (1) BRPI0512941A (pt)
CA (1) CA2571944A1 (pt)
IL (1) IL180458A0 (pt)
MX (1) MXPA06015239A (pt)
NO (1) NO20070563L (pt)
NZ (2) NZ552730A (pt)
RU (2) RU2428429C2 (pt)
WO (1) WO2006083317A2 (pt)
ZA (1) ZA200610818B (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
SK287315B6 (sk) * 2006-06-02 2010-06-07 Biotika, A. S. Spôsob izolácie polymyxínu B z vyfermentovanej pôdy
CN101501063B (zh) * 2006-08-11 2014-03-12 北方抗生素有限公司 多粘菌素衍生物及其用途
US7807637B2 (en) * 2006-08-11 2010-10-05 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
US9096649B2 (en) 2008-02-08 2015-08-04 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
US8193148B2 (en) 2008-02-08 2012-06-05 Northern Antibiotics Ltd. Short fatty acid tail polymyxin derivatives and uses thereof
FI20085469A0 (fi) 2008-02-08 2008-05-16 Northern Antibiotics Oy Polymyksiinijohdannaiset, joissa on lyhyt rasvahappohäntä, ja niiden käyttöjä
US8329645B2 (en) * 2008-02-08 2012-12-11 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
CN101970462B (zh) * 2008-03-14 2013-06-19 安斯泰来制药株式会社 环状化合物及其盐
NZ593892A (en) 2008-12-23 2013-11-29 Biosource Pharm Inc Antibiotic compositions for the treatment of gram negative infections
WO2010130007A1 (en) * 2009-05-14 2010-11-18 Monash University Antimicrobial compounds
ES2374779B1 (es) * 2010-03-10 2012-12-27 Universidad De Barcelona Compuestos péptidicos útiles como agentes antibacterianos.
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2012051663A1 (en) * 2010-10-21 2012-04-26 Monash University Antimicrobial compounds
WO2012168820A1 (en) * 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin derivatives useful as antibacterial agents
CA2855916A1 (en) 2011-11-18 2013-05-23 Novacta Biosystems Limited Polymyxin derivatives
EP2679236A1 (de) 2012-06-29 2014-01-01 Zentrum für biomedizinische Technologie der Donau- Universität Krems Dosierungsanleitung für endotoxinbindende Lipopeptide
RS63484B1 (sr) 2013-05-22 2022-09-30 Spero Therapeutics Inc Derivati polimiksina i njihova upotreba u kombinovanoj terapiji zajedno sa različitim antibioticima
CN103396475B (zh) * 2013-08-06 2015-08-26 深圳翰宇药业股份有限公司 一种纯固相合成多肽类抗生素Colistin的方法
JP6754997B2 (ja) 2013-08-26 2020-09-16 国立大学法人 東京大学 大環状ペプチド、その製造方法、及び大環状ペプチドライブラリを用いるスクリーニング方法
WO2015135976A1 (en) * 2014-03-11 2015-09-17 New Pharma Licence Holdings Limited Polymyxin derivatives and their use in combination therapy together with different antibiotics
JP2017512818A (ja) * 2014-04-01 2017-05-25 モナシュ、ユニバーシティＭｏｎａｓｈ Ｕｎｉｖｅｒｓｉｔｙ 抗菌性化合物としてのポリミキシン誘導体
CN103993059B (zh) * 2014-05-28 2016-08-17 河北圣雪大成制药有限责任公司 优化多粘芽孢杆菌发酵液中e1和e2组分比例的方法
US11466050B2 (en) * 2014-09-29 2022-10-11 Sulfotools Gmbh Method for peptide synthesis and apparatus for carrying out a method for solid phase synthesis of peptides
GB2530776A (en) * 2014-10-01 2016-04-06 Randox Lab Ltd Detection of polymyxins
JP6896628B2 (ja) 2014-12-16 2021-06-30 シャンハイ ミクウルク ファーマシューティカル シーオー．エルティーディー 細菌感染症の治療のための抗微生物性ポリミキシン
JO3669B1 (ar) * 2015-01-06 2020-08-27 Ferring Bv بيبتيدات مضَادَّة لببتيد المرتبط بجين الكالسيتونين
FI126143B (en) 2015-01-15 2016-07-15 Northern Antibiotics Oy Polymyxine derivative and its uses
US9763996B2 (en) 2015-01-16 2017-09-19 Northern Antibiotics, Ltd. Polymyxin derivative and uses thereof
AU2016331658B2 (en) * 2015-09-29 2021-04-01 Monash University Antimicrobial polymyxin derivative compounds
CR20180232A (es) 2015-10-27 2018-05-31 Hoffmann La Roche Macrociclos peptídicos contra acinetobacter baumannii
CA3036095A1 (en) 2016-09-13 2018-03-22 Allergan, Inc. Stabilized non-protein clostridial toxin compositions
US20190315806A1 (en) * 2016-12-16 2019-10-17 Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences Polymyxin derivative, preparation method and application thereof
CN106868079B (zh) * 2017-04-26 2020-12-08 山东鲁抗医药股份有限公司 发酵硫酸多粘菌素b用培养基及发酵生产硫酸多粘菌素b的方法
JP2021501783A (ja) * 2017-11-02 2021-01-21 ザ ユニバーシティー オブ クイーンズランド ペプチド抗生物質
US11819532B2 (en) 2018-04-23 2023-11-21 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
JP7488774B2 (ja) 2018-06-25 2024-05-22 スペロ・セラピューティクス・インコーポレーテッド 化合物
CN115298198A (zh) 2020-01-21 2022-11-04 上海盟科药业股份有限公司 用于肾相关癌症靶向治疗的新型化合物和组合物
CN111410682A (zh) * 2020-04-28 2020-07-14 梯尔希（南京）药物研发有限公司 多粘菌素b相关化合物的环化制备方法
CN113215185B (zh) * 2021-04-22 2022-04-29 浙江工业大学 一种用于重组表达棘白菌素b脱酰基酶的重组基因序列
CN113174398B (zh) * 2021-04-22 2022-04-29 浙江工业大学 一种用于重组表达棘白菌素b脱酰基酶的表达盒及应用

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3753970A (en) 1970-08-04 1973-08-21 Rhone Poulenc Sa Cyclopeptides derived from polymyxins and their preparation
FR2124060B1 (pt) * 1971-02-02 1974-04-12 Rhone Poulenc Sa
US4091092A (en) * 1976-09-20 1978-05-23 E. R. Squibb & Sons, Inc. Polymyxin F and process of producing polymyxin F
US5366734A (en) 1981-02-16 1994-11-22 Zeneca Limited Continuous release pharmaceutical compositions
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3376424D1 (en) 1982-02-27 1988-06-01 Beecham Group Plc Antibacterial 1-normon-2-yl-heterocyclic compounds
ATE37983T1 (de) * 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
USRE32311E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4399067A (en) * 1982-05-21 1983-08-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4524135A (en) * 1982-05-21 1985-06-18 Eli Lilly And Company A-21978C cyclic peptides
USRE32310E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
GB2128617A (en) * 1982-10-06 1984-05-02 Martti Vaara Polypeptides for use in antibacterial therapy
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4601893A (en) * 1984-02-08 1986-07-22 Pfizer Inc. Laminate device for controlled and prolonged release of substances to an ambient environment and method of use
US4895566A (en) * 1986-07-25 1990-01-23 C. R. Bard, Inc. Coating medical devices with cationic antibiotics
CA1332940C (en) * 1986-08-07 1994-11-08 Henrich Hasko Paradies N-alkylated quaternary nitrogen-containing heterocycles
US4830860A (en) * 1986-10-30 1989-05-16 Pfizer Inc. Stressed polymeric device for controlled release of a substance to an ambient environment
US5755788A (en) * 1987-02-19 1998-05-26 Rutgers, The State University Prosthesis and implants having liposomes bound thereto and methods of preparation
US20010021697A1 (en) * 1987-09-14 2001-09-13 Henning Lowenstein Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom, proteinageous or polypeptide components thereof, or analogues of such proteinaceous or polypeptide components
US5039789A (en) * 1988-04-11 1991-08-13 Eli Lilly And Company A54145 cyclic peptides
US5028590A (en) 1988-04-11 1991-07-02 Eli Lilly And Company Derivatives of A54145 cyclic peptides
US5254535A (en) * 1989-04-17 1993-10-19 The Children's Hospital Of Pennsylvania Composition and treatment with biologically active peptides and antibiotic
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5459237A (en) * 1990-02-08 1995-10-17 Magainin Pharmaceuticals Inc. Peptide compositions and uses therefor
JPH04167172A (ja) * 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
US5082653A (en) * 1990-10-31 1992-01-21 Warner-Lambert Company Anti-plaque compositions comprising a combination of morpholinoamino alcohol and antibiotic
US5686065A (en) * 1991-03-27 1997-11-11 Special Advanced Biomaterials, Inc. Topical siloxane sunscreen compositions having enhanced performance and safety
EP0579763A4 (en) * 1991-04-08 1994-12-21 Magainin Pharma NOVEL PEPTIDE COMPOSITIONS AND USES.
EP0667871A1 (en) 1991-09-13 1995-08-23 Magainin Pharmaceuticals Inc. Biologically active amphiphilic peptide compositions and uses therefor
TW274552B (pt) * 1992-05-26 1996-04-21 Hoechst Ag
US6348445B1 (en) * 1992-06-01 2002-02-19 Magainin Pharmaceuticals, Inc. Biologically active peptides with reduced toxicity in animals and a method for preparing same
US5283005A (en) * 1992-10-08 1994-02-01 Olin Corporation Synergistic biocide combination for industrial fluids
US5424290A (en) * 1992-10-26 1995-06-13 Magainin Pharmaceuticals Inc. Biologically active peptides and uses therefor
US5360788A (en) 1992-11-10 1994-11-01 Olin Corporation Personal care composition containing pyrithione and a basic lipopeptide
US5370876A (en) * 1993-01-08 1994-12-06 Microbarriers Antimicrobial protective skin composition and method for protecting skin from body fluids
US5654451B1 (en) * 1993-01-14 2000-02-22 Magainin Pharma Amino acids and peptides having modified c-terminals and modified n-terminals
CA2112776C (en) * 1993-01-21 2002-11-12 Masakazu Tsuchiya Process for inhibiting activity of endotoxin
US5733872A (en) * 1993-03-12 1998-03-31 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5652332A (en) 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US20040023884A1 (en) * 1993-03-12 2004-02-05 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US6180134B1 (en) * 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
US5635216A (en) * 1993-12-16 1997-06-03 Eli Lilly And Company Microparticle compositions containing peptides, and methods for the preparation thereof
WO1995005384A1 (en) 1993-08-13 1995-02-23 Smithkline Beecham Plc Derivatives of monic acids a and c having antibacterial, antimycoplasmatical, antifungal and herbicidal activity
US5587358A (en) * 1994-05-09 1996-12-24 Asahi Kasei Kogyo Kabushiki Kaisha Potentiators of antimicrobial activity
FR2735983B1 (fr) * 1995-06-29 1997-12-05 Centre Nat Rech Scient Peptide permettant de modifier l'activite du systeme immunitaire humain ou animal
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US20020150964A1 (en) * 1995-12-19 2002-10-17 Centre National De La Recherche Scientifique Peptides for the activation of the immune system in humans and animals
US6011008A (en) * 1997-01-08 2000-01-04 Yissum Research Developement Company Of The Hebrew University Of Jerusalem Conjugates of biologically active substances
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6350438B1 (en) * 1998-02-27 2002-02-26 The Procter & Gamble Company Oral care compositions comprising chlorite and methods
US6846478B1 (en) * 1998-02-27 2005-01-25 The Procter & Gamble Company Promoting whole body health
US6350738B1 (en) * 1998-03-06 2002-02-26 Brigham Young University Steroid derived antibiotics
US6767904B2 (en) * 1998-03-06 2004-07-27 Bringham Young University Steroid derived antibiotics
US6468967B1 (en) * 1998-09-25 2002-10-22 Cubist Pharmaceuticals, Incorporated Methods for administration of antibiotics
IT1308180B1 (it) * 1999-02-12 2001-12-07 Chiesi Farma Spa Peptidi sintetici aventi la capacita' di diminuire la tensionesuperficiale e loro impiego nella preparazione di un surfattante
US6964948B2 (en) * 1999-06-25 2005-11-15 Xoma Technology Ltd. Therapeutic peptide-based constructs derived from Domain II of bactericidal/permeability-increasing protein
US6515104B1 (en) * 1999-06-25 2003-02-04 Xoma Technology Ltd. Therapeutic peptide-based constructs derived from domain II of bactericidal/permeability-increasing protein
CA2378868A1 (en) * 1999-07-15 2001-01-25 Eli Lilly And Company Process for deacylation of lipodepsipeptides
US6380356B1 (en) * 1999-12-07 2002-04-30 Advanced Medicine, Inc. Multivalent polymyxin antibiotics
AU784755B2 (en) 1999-12-15 2006-06-08 Merck Sharp & Dohme Corp. Daptomycin Analogs as antibacterial agents
KR20020063228A (ko) 1999-12-15 2002-08-01 큐비스트 파마슈티컬즈 인코포레이티드 항균제로서 리포펩티드
CA2394313A1 (en) 1999-12-15 2001-06-21 Cubist Pharmaceuticals, Inc. Novel lipopeptides as antibacterial agents
US7074392B1 (en) * 2000-03-27 2006-07-11 Taro Pharmaceutical Industries Limited Controllled delivery system of antifungal and keratolytic agents for local treatment of fungal infections
JP3292723B2 (ja) * 2000-05-26 2002-06-17 アルス電子株式会社 半導体パッケージ及びその製造方法
WO2001091814A2 (en) * 2000-05-30 2001-12-06 Viridis Biotech Inc. Polyubiquitin based hydrogel and uses thereof
MXPA03000041A (es) * 2000-06-30 2003-10-15 Procter & Gamble Composiciones orales que comprenden agentes microbianos.
WO2002005837A1 (en) 2000-07-17 2002-01-24 Intrabiotics Pharmaceuticals, Inc. Antimicrobial sulfonamide derivatives of lipopeptide antibiotics
US6511962B1 (en) * 2000-07-17 2003-01-28 Micrologix Biotech Inc. Derivatives of laspartomycin and preparation and use thereof
ATE500277T1 (de) * 2001-01-16 2011-03-15 Univ Ramot Hybridpeptide für die behandlung von bacteraemie und sepsis
HUP0401305A2 (hu) * 2001-01-31 2004-10-28 Pfizer Products Inc. Tiazolil-, oxazolil-, pirrolil- és imidazolil-savamid-származékok, mint PDE4 izozimek inhibitorai és az ezeket tartalmazó gyógyszerkészítmények
WO2002074316A1 (en) * 2001-03-15 2002-09-26 Enteron Pharmaceuticals, Inc. Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
EP1423414A4 (en) 2001-08-06 2005-11-30 Cubist Pharm Inc NEW DEPSIPEPTIDES AND METHOD FOR THE PRODUCTION THEREOF
US6681765B2 (en) 2001-12-18 2004-01-27 Sheree H. Wen Antiviral and antibacterial respirator mask
US7345018B2 (en) * 2002-04-25 2008-03-18 Reception Aps Method of treating side effects induced by therapeutic agents
EP1360961A1 (en) 2002-05-07 2003-11-12 AM-Pharma B.V. Use of antimicrobial peptides for potentiating the activity of antimicrobial agents
US6767718B2 (en) 2002-05-10 2004-07-27 Biosource Pharm, Inc. Lipodepsipeptide antibiotics and methods of preparation
WO2004014322A2 (en) * 2002-08-12 2004-02-19 Dynavax Technologies Corporation Immunomodulatory compositions, methods of making, and methods of use thereof
US20040037895A1 (en) * 2002-08-23 2004-02-26 Alex Zhu Methods of treating involuntary facial spasms and facial wrinkles
US20090123367A1 (en) * 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
EA009598B1 (ru) * 2003-05-16 2008-02-28 Синвеншн Аг Медицинские имплантаты, содержащие биосовместимые покрытия
MXPA06003573A (es) 2003-09-30 2006-08-31 Kohi Corp Composiciones y metodos para tratar quemaduras.
WO2005065079A2 (en) 2003-11-10 2005-07-21 Angiotech International Ag Medical implants and fibrosis-inducing agents
US7364747B1 (en) * 2004-02-02 2008-04-29 S.S. Steiner, Inc. Process and product for inhibiting or preventing bacterial infections
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
CA2572442A1 (fr) * 2004-07-30 2006-03-09 Palumed S.A. Molecules hybrides qa ou q est une aminoquinoleine et a est un residu antibiotique, leur synthese et leurs utilisations en tant qu'agent antibacterien
US7541046B1 (en) * 2005-01-04 2009-06-02 Gp Medical, Inc. Nanoparticles for protein drug delivery
ES2558534T3 (es) * 2005-02-18 2016-02-05 The Cleveland Clinic Foundation Aparato para sustituir una válvula cardíaca
EP1893131A1 (en) 2005-04-20 2008-03-05 The Cleveland Clinic Foundation Apparatus and method for replacing a cardiac valve
DE602006009113D1 (de) * 2005-07-15 2009-10-22 Cleveland Clinic Foundation Vorrichtung zur Ummodellierung eines Herzklappenrings
US20070299043A1 (en) 2005-10-03 2007-12-27 Hunter William L Anti-scarring drug combinations and use thereof
US20070196421A1 (en) * 2005-10-03 2007-08-23 Hunter William L Soft tissue implants and drug combination compositions, and use thereof
WO2007041593A2 (en) * 2005-10-03 2007-04-12 Combinatorx, Incorporated Anti-scarring drug combinations and use thereof
US20070197957A1 (en) * 2005-10-03 2007-08-23 Hunter William L Implantable sensors, implantable pumps and anti-scarring drug combinations
KR100750658B1 (ko) * 2005-12-09 2007-08-20 한국생명공학연구원 폴리믹신 생합성 효소 및 이를 코딩하는 유전자 군
CA2632871A1 (en) * 2006-01-30 2007-08-09 Angiotech Pharmaceuticals, Inc. Sutures and fibrosing agents
US9155792B2 (en) * 2006-02-13 2015-10-13 Trustees Of Boston University RecA inhibitors with antibiotic activity, compositions and methods of use
WO2007095631A2 (en) * 2006-02-15 2007-08-23 The Regents Of The University Of California New drug delivery system for crossing the blood brain barrier
WO2007100663A2 (en) * 2006-02-22 2007-09-07 University Of Kansas Polyamines and their use as antibacterial and sensitizing agents
US8585753B2 (en) * 2006-03-04 2013-11-19 John James Scanlon Fibrillated biodegradable prosthesis
US20070243275A1 (en) * 2006-04-13 2007-10-18 Gilbard Jeffrey P Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear
US8652201B2 (en) * 2006-04-26 2014-02-18 The Cleveland Clinic Foundation Apparatus and method for treating cardiovascular diseases
US8771712B2 (en) * 2006-05-09 2014-07-08 Emisphere Technologies, Inc. Topical administration of acyclovir
CN101511430A (zh) 2006-08-03 2009-08-19 普罗森萨技术有限公司 抗生素组合物
CN101501063B (zh) 2006-08-11 2014-03-12 北方抗生素有限公司 多粘菌素衍生物及其用途
US7807637B2 (en) 2006-08-11 2010-10-05 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
US20100028334A1 (en) * 2006-12-15 2010-02-04 Trustees Of Boston University Compositions and methods to potentiate colistin activity
EP2526773A1 (en) * 2007-04-02 2012-11-28 Mount Sinai School Of Medicine Methods for preventing or treating infectious diseases using gallium compounds
US20090048155A1 (en) * 2007-08-15 2009-02-19 Endacea, Inc. Methods for preventing and treating tissue injury and sepsis associated with Yersinia pestis infection
US20090214601A1 (en) * 2007-09-28 2009-08-27 Chappa Ralph A Porous Drug Delivery Devices and Related Methods
US20090227018A1 (en) * 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US8193148B2 (en) * 2008-02-08 2012-06-05 Northern Antibiotics Ltd. Short fatty acid tail polymyxin derivatives and uses thereof
US8329645B2 (en) * 2008-02-08 2012-12-11 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
NZ593892A (en) 2008-12-23 2013-11-29 Biosource Pharm Inc Antibiotic compositions for the treatment of gram negative infections
US8415307B1 (en) * 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections

Also Published As

Publication number Publication date
EP2332965A1 (en) 2011-06-15
CN101010336A (zh) 2007-08-01
WO2006083317A3 (en) 2007-01-18
RU2428429C2 (ru) 2011-09-10
US20080207874A1 (en) 2008-08-28
EP1761554A2 (en) 2007-03-14
IL180458A0 (en) 2007-06-03
AU2005326770B2 (en) 2011-11-03
MXPA06015239A (es) 2007-12-10
RU2007103811A (ru) 2008-08-10
CA2571944A1 (en) 2006-08-10
RU2011115077A (ru) 2012-10-20
AU2005326770A1 (en) 2006-08-10
WO2006083317A9 (en) 2007-03-01
KR20070047770A (ko) 2007-05-07
US20060004185A1 (en) 2006-01-05
NZ552730A (en) 2009-09-25
US8889826B2 (en) 2014-11-18
ZA200610818B (en) 2008-07-30
WO2006083317A2 (en) 2006-08-10
JP2011256189A (ja) 2011-12-22
JP2008505858A (ja) 2008-02-28
NO20070563L (no) 2007-03-27
NZ579261A (en) 2011-02-25

Similar Documents

Publication Publication Date Title
BRPI0512941A (pt) antibióticos de peptìdeo e métodos para fazer os mesmos
IL232501A (en) Peptide or polypeptide-resistant protein analogs and their uses
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
ZA200705179B (en) Immunogenic compositions of cyclic peptides derived from the beta-amyloid peptide
TNSN06222A1 (en) Pharmaceutical formulations comprising metformin and a fibrate, and processes for obtaining them
ATE404225T1 (de) Radiofluorierte peptide
HK1129581A1 (pt)
WO2007115571A8 (en) Erbb receptor-derived peptide fragments
MX2007005221A (es) Formas cristalinas de ascomicina y preparacion de ellas.
BRPI0512347B8 (pt) preparação da pregabalina e compostos relacionados
TWI367880B (en) Carbazole compounds
TW200718676A (en) Tigecycline and methods of preparation
NZ612161A (en) Radiolabled her2 binding peptides
MX2010004571A (es) Composiciones y metodos que comprenden peptidos y proteasas de aminoacidos basicos.
TN2009000194A1 (en) Novel antiproliferation antibodies
MX2009005460A (es) (s)-n-estereoisomeros de analogos de 7,8-saturados-4,5-epoxi-morfi nano.
MX2009013354A (es) Compuestos de triarilo y composiciones que los contienen.
NZ609916A (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
EA200800253A1 (ru) Бессывороточная культуральная среда для получения рекомбинантных гонадотропинов
WO2005097203A3 (en) Serum protein conjugates of ion channel modulating compounds and uses thereof
WO2009080764A3 (en) Oral or nasal administration of compounds comprising amino acid sequences
WO2007103739A3 (en) Methods and compositions related to cyclic peptide synthesis
WO2011100688A8 (en) Improved antagonists of muc1
WO2006103101A3 (en) MEANS FOR THE INHIBITION OF ANTI-β1-ADRENERGIC RECEPTOR ANTIBODIES
WO2008072976A3 (en) Synthesis of a radiofluorinated peptide using microwave activation technology

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2154 DE 17/04/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2261 DE 06/05/2014.